NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Anumana

Anumana

Private
Cambridge, MassachusettsHealthcare & Life Scienceshttps://anumana.ai/

Last Round

Series C

Apr 24, 2025

Total Funding Raised

$181.1M

Momentum

Top 25%

of companies Caplight tracks

Company Overview

Anumana is a health technology company that develops AI-driven ECG algorithms to enhance early diagnosis and treatment through advanced predictive tools and biomarkers of disease.

Sector

Healthcare & Life Sciences

Verticals

Medical AI, Medical Devices, Healthcare Analytics

Business Model

B2B

Customer Profile

Usage-Based SaaS, Services & Consulting

AI Layer

Application

Keywords

software as a medical deviceSaMDECG AIcardiovascular AIdiagnostic decision supportclinical AIAI diagnosticsmedical imaging AIcardiac screeninghealth techFDA cleared AIdigital healthclinical workflow integrationAI in cardiologysmart diagnostics

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Anumana Comps

Public and private peers based on sector, stage, and business model.

Anumana comps — public and private peers by sector, stage, and business model
CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

Anumana Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series CApr 24, 2025
Series BJun 1, 2022
Series AApr 14, 2021
View all Funding Rounds

Key People

Founding team and executive leadership

Harry Palmin

CFO

Executive Team

Anumana Investors

Notable investors and investment history

Anumana investors
InvestorRounds
MatrixSeries C, Series B, Series A
Matrix Capital ManagementSeries C, Series A
NTTVCSeries C, Series B, Series A
View all Investors

Market signals

Structured signals derived from secondary market and firmographic data.

  • Apr 8, 2026

    FDA-cleared AI software for cardiac amyloidosis diagnosis launched.

  • Apr 8, 2026

    AI software for cardiac amyloidosis detection receives FDA clearance.

View all signals

Anumana Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Anumana Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Anumana's valuation, stock price, and market status.

Firmographic Details

HeadquartersCambridge, Massachusetts
Employee Range183
Year Founded2021
Last FundingApr 24, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.